How do I install the Ppgl 68ga Dotatate Pet Indication skill?

Run npx skillmds@latest add dromlakhani/ppgl-68ga-dotatate-pet-indication in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Ppgl 68ga Dotatate Pet Indication safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Ppgl 68ga Dotatate Pet Indication?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Ppgl 68ga Dotatate Pet Indication free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Ppgl 68ga Dotatate Pet Indication?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Ppgl 68ga Dotatate Pet Indication by dromlakhani

Name: Ppgl 68ga Dotatate Pet Indication
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Ppgl 68ga Dotatate Pet Indication

Determines when to use 68Ga-DOTATATE PET for diagnosing primary head and neck paragangliomas irrespective of genetic variants. Triggers include suspected head/neck PGL requiring sensitive detection, evaluating for SSTR-positive neuroendocrine tumor, and pre-assessment for 177Lu-DOTATATE therapy in HNPGL.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

68Ga-DOTATATE PET Indication for Head/Neck PGL

STEP 1 — Gather Information

Collect clinical suspicion of head/neck PGL (e.g., neck mass, cranial nerve palsies, pulsatile tinnitus), biochemical workup (fractionated metanephrines/catecholamines), anatomic imaging (contrast-enhanced MRI of head and neck ± skull base CT), and prior functional imaging if available (e.g., 123I-MIBG scintigraphy). Genetic testing is not required for indication but may be recorded.

STEP 2 — Rule In / Rule Out

If head/neck PGL is suspected based on clinical or imaging findings → proceed to 68Ga-DOTATATE PET; otherwise, consider alternative diagnostics and do not order the scan.

STEP 3 — Classify or Stratify

Interpret 68Ga-DOTATATE PET: SSTR-positive uptake in a head/neck lesion consistent with PGL → classify as SSTR-positive HNPGL; absent or non-specific uptake → classify as SSTR-negative or indeterminate.

STEP 4 — Decide

For SSTR-positive HNPGL, consider 177Lu-DOTATATE peptide receptor radionuclide therapy if therapeutic intervention is indicated; for SSTR-negative or indeterminate results, rely on anatomic imaging and biopsy (if safe) or alternative functional imaging (e.g., 18F-FDG PET) for further evaluation.

Clinical Guardrails / Mimics / Pitfalls

68Ga-DOTATATE PET is not covered by Japanese health insurance; physiologic uptake in salivary glands, tonsils, and lymphoid tissue can mimic disease—correlate with anatomic imaging. False negatives may occur in very small tumors (<5 mm) or due to high blood glucose causing brown adipose tissue uptake; advise fasting and warm environment. Do not use as a sole diagnostic test without histologic or biochemical confirmation when feasible.

Concrete Clinical Example

A 48‑year‑old woman presented with a left carotid body tumor and normal plasma metanephrines. Contrast MRI showed a 1.2 cm flow‑void lesion. 68Ga‑DOTATATE PET/CT demonstrated intense focal uptake in the lesion (SUVmax 12.4), confirming SSTR‑positive HNPGL. She was referred for 177Lu‑DOTATATE therapy after multidisciplinary review.

Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165

---name: ppgl-68ga-dotatate-pet-indicationdescription: Determines when to use 68Ga-DOTATATE PET for diagnosing primary head and neck paragangliomas irrespective of genetic variants. Triggers include suspected head/neck PGL requiring sensitive detection, evaluating for SSTR-positive neuroendocrine tumor, and pre-assessment for 177Lu-DOTATATE therapy in HNPGL.---# 68Ga-DOTATATE PET Indication for Head/Neck PGL## STEP 1 — Gather InformationCollect clinical suspicion of head/neck PGL (e.g., neck mass, cranial nerve palsies, pulsatile tinnitus), biochemical workup (fractionated metanephrines/catecholamines), anatomic imaging (contrast-enhanced MRI of head and neck ± skull base CT), and prior functional imaging if available (e.g., 123I-MIBG scintigraphy). Genetic testing is not required for indication but may be recorded.## STEP 2 — Rule In / Rule OutIf head/neck PGL is suspected based on clinical or imaging findings → proceed to 68Ga-DOTATATE PET; otherwise, consider alternative diagnostics and do not order the scan.## STEP 3 — Classify or StratifyInterpret 68Ga-DOTATATE PET: SSTR-positive uptake in a head/neck lesion consistent with PGL → classify as SSTR-positive HNPGL; absent or non-specific uptake → classify as SSTR-negative or indeterminate.## STEP 4 — DecideFor SSTR-positive HNPGL, consider 177Lu-DOTATATE peptide receptor radionuclide therapy if therapeutic intervention is indicated; for SSTR-negative or indeterminate results, rely on anatomic imaging and biopsy (if safe) or alternative functional imaging (e.g., 18F-FDG PET) for further evaluation.## Clinical Guardrails / Mimics / Pitfalls68Ga-DOTATATE PET is not covered by Japanese health insurance; physiologic uptake in salivary glands, tonsils, and lymphoid tissue can mimic disease—correlate with anatomic imaging. False negatives may occur in very small tumors (<5 mm) or due to high blood glucose causing brown adipose tissue uptake; advise fasting and warm environment. Do not use as a sole diagnostic test without histologic or biochemical confirmation when feasible.## Concrete Clinical ExampleA 48‑year‑old woman presented with a left carotid body tumor and normal plasma metanephrines. Contrast MRI showed a 1.2 cm flow‑void lesion. 68Ga‑DOTATATE PET/CT demonstrated intense focal uptake in the lesion (SUVmax 12.4), confirming SSTR‑positive HNPGL. She was referred for 177Lu‑DOTATATE therapy after multidisciplinary review.**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165

Frequently asked questions